201. Unique allergen-specific human IgE monoclonal antibodies derived from patients with allergic disease.
- Author
-
Smith BRE, Reid Black K, Bermingham M, Agah S, Glesner J, Versteeg SA, van Ree R, Pena-Amelunxen G, Aglas L, Smith SA, Pomés A, and Chapman MD
- Abstract
Introduction: Allergic reactions are mediated by human IgE antibodies that bind to and cross-link allergen molecules. The sites on allergens that are recognized by IgE antibodies have been difficult to investigate because of the paucity of IgE antibodies in a human serum. Here, we report the production of unique human IgE monoclonal antibodies to major inhaled allergens and food allergens that can be produced at scale in perpetuity., Materials and Methods: The IgE antibodies were derived from peripheral blood mononuclear cells of symptomatic allergic patients, mostly children aged 3-18 years, using hybridoma fusion technology. Total IgE and allergen-specific IgE was measured by ImmunoCAP. Their specificity was confirmed through ELISA and immunoblotting. Allergenic potency measurements were determined by ImmunoCAP inhibition. Biological activity was determined in vitro by comparing β -hexosaminidase release from a humanized rat basophilic cell line., Results: Human IgE monoclonal antibodies ( n = 33) were derived from 17 allergic patients with symptoms of allergic rhinitis, asthma, atopic dermatitis, food allergy, eosinophilic esophagitis, or red meat allergy. The antibodies were specific for five inhaled allergens, nine food allergens, and alpha-gal and had high levels of IgE (53,450-1,702,500 kU/L) with ratios of specific IgE to total IgE ranging from <0.01 to 1.39. Sigmoidal allergen binding curves were obtained through ELISA, with low limits of detection (<1 kU/L). Allergen specificity was confirmed through immunoblotting. Pairs of IgE monoclonal antibodies to Ara h 6 were identified that cross-linked after allergen stimulation and induced release of significant levels of β -hexosaminidase (35%-80%) from a humanized rat basophilic cell line., Conclusions: Human IgE monoclonal antibodies are unique antibody molecules with potential applications in allergy diagnosis, allergen standardization, and identification of allergenic epitopes for the development of allergy therapeutics. The IgE antibody probes will enable the unequivocal localization and validation of allergenic epitopes., Competing Interests: The research approach was developed by several authors who are employees of InBio (BS, KR, MB, SA, JG, AP, and MC). The hIgE mAb and some allergens used in this study were produced by InBio. AP is a contact principal investigator of the NIH R01 award that provided funding for the study. MC has a financial interest in InBio and is a co-investigator for the NIH R01 award. InBio has a license agreement with Vanderbilt University Medical Center for the commercialization of the hIgE mAb for research and diagnostic purposes. The hIgE mAb covered by this agreement are available from InBio (www.inbio.com). SS is an inventor on US patent 10908168-B2 for the generation of human IgE monoclonal antibodies, has received patent royalties, and has related patents pending. RR is a consultant for HAL Allergy BV, Citeq BV, Angany Inc., Reacta Healthcare Ltd., Mission MightyMe, and AB Enzymes; receives speaker fees from HAL Allergy BV, ALK, and Thermo Fisher Scientific; and has stock options with Angany Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (© 2023 Smith, Reid Black, Bermingham, Agah, Glesner, Versteeg, van Ree, Pena-Amelunxen, Aglas, Smith, Pomés and Chapman.)
- Published
- 2023
- Full Text
- View/download PDF